Receptor Tyrosine Kinases 1 Flashcards

1
Q

20 RTK subfamilies

TRUE OR FALSE

A

TRUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Structure of RTKs:

A

Ligand Binding Domain (Extracellular)
Transmembrane Domain
Tyrosine Kinase Domain (Cytoplasmic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

RTK Activation:

A

Most RTKs are expressed an inactive monomers

Ligand binding promotes dimerization and receptor activation

  • Insulin / IGF receptors are an exception: exist as a “dimer” joined by a disulphide bridge
  • Different RTKs form dimers in different ways
  • Dimerisation promotes activation of the tyrosine kinase domain; precise mechanism varies in different receptors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

3 Different ways in which RTKs form dimers

A
  1. Each ligand binds only one receptor, Ligand does not contribute to dimer interface e.g. EGF Receptor
  2. Both ligand and receptor contribute to dimer interface e.g. C-Kit Receptor
  3. Dimeric ligands results in dimer – no direct contribution of ligand binding domain in dimer e.g. Trk (NGF) receptor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

EGF / ErbB receptor activation:

A

Transmembrane receptor, found on the plasma membrane

Inactive ErbB receptors are present as monomers on the plasma membrane

Can dimerise, however ligand binding drives dimerization and subsequent activation

Can activate signaling as a homodimer or as a heterodimer with another ErbB family member

EGF binding leads to activation of the tyrosine kinase domain

This results in autophosphorylation on multiple tyrosines in the cytoplasmic domain of the receptor

This creates binding sites signaling adaptors such as Shc and Grb which process phosphotyrosine binding motifs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

EGF receptor:

A

Member of the ErbB family of RTKs:

  • EGFR
  • ErbB2
  • ErbB3
  • ErbB4

ErbB receptors can bind multiple ligands

ErbB2 is an orphan receptor; can dimerise with other ErbB receptors

ErbB3 is kinase inactive – does not signal as a homodimer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Signaling adaptors

A

Protein interactions are mediated by distinct, highly discerning, independently folded domains
These domains can recognize post translational modification such as phosphorylation

Signaling adaptors use combinations of these protein recognition domains to assemble complexes of signaling enzymes
Typically adaptors do not have any catalytic activity

Shc and Grb are the key adaptors that link EGF receptor activation to MAPK pathways
Bind to phospho-tyrosine residues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

SH2 domains

A

Examples found in many proteins
All bind phospho-Tyr, binding also affected by the amino acid sequence around the p-Y residue: different SH2 domains recognize different p-Y motifs

The ability of SH2 and PTB domains to bind to specific pTyr residues depending on the surrounding sequence means that all SH2 / PTB domain containing proteins will not be recruited to individual tyrosine phosphorylated proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

PTB: “phosphotyrosine binding domain”

A

Examples found in several proteins
Binds to phospho-Tyr; preferred recognition motif is N-P-x-pY

The ability of SH2 and PTB domains to bind to specific pTyr residues depending on the surrounding sequence means that all SH2 / PTB domain containing proteins will not be recruited to individual tyrosine phosphorylated proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Shc:

A

ShcA was one of the first adaptors to be described

Alternate start codons results in 3 different isoforms

ShcA widely expressed, but downregulated in mature CNS neurons

ShcB and C expressed in the CNS and may replace ShcA

ShcD differentially expressed during development

Contain PTB and SH2 domains

ShcA binds to p-Y of the EGF receptor

Y992 binds the SH2 domain while Y1148 or Y1173 binds the PTB domain

Other p-Y may also contribute

PTB binding appears to be more important than SH2 in order to promote a strong MAPK activation

Once bound, ShcA is phosphorylated by the EGFR domain.

Phosphorylated ShcA recruits a 2nd adaptor Grb2

Grb2 can also bind to the EGFR independently of ShcA

While Gbr2 can bind to the receptor without ShcA, the ShcA pathway is more efficient and promotes signaling at low concretions of EGF receptor ligands

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Grb2

A

Grb2 is a small adaptor protein containing an SH2 domain flanked by SH3 domains

SH3 domains bind Pro – X – X – Pro motifs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Grb2 activates the classical MAPK cascade

TRUE OR FALSE

A

TRUE
Grb2 is constitutively bound to SOS. Recruitment of Grb2 to the EGFR brings SOS to the membrane where is acts as a GEF for Ras

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

MAPK signalling:

A

MAPKs are present in all eukaryotes

In addition to RTKs, other receptors (eg GPCRs, cytokine receptors and ligand gated ion channels) also activate MAPKs

Mammalian cells have 14 MAPK genes:

  • “Classical MAPKs”; ERK1, ERK2
  • P38 MAPKs; p38a, p38b, p38g, p38d
  • Jun N-terminal kinases; JNK1, JNK2, JNK3
  • Atypical MAPKs; ERK3, ERK4, ERK5, ERK7, NLK

Wide range of substrates and functions:

  • eg: cell proliferation, survival, development immune function, neuronal function, regulation of metabolism
  • ERK1/2 and p38 activate further downstream kinases

Each MAPK cascade has specific MAP2K and MAP3K enzymes

MAP3K: MAPK kinase kinases phosphorylate and activate MAP2Ks. They can be activated by other kinases or by interactions with other signaling proteins such as small GTPases

MAP2K: MAPK kinases phosphorylate both the Tyr and Thr residues in the TXY motif. This makes them unusual as they have both Ser/Thr and Tyr kinase activity

MAPK: MAPKs are activated by phosphorylation of a TXY motif in the activation loop of their kinase domain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Gab proteins mediate PI3K and PLCgamma activation

A

3 isoforms, Gab1 ,2 and 3
Have an N terminal PH domain and P-X-X-P motifs (SH3 binding)
Recruited to membranes via their PH domain and via interaction with Grb2

Following recruitment to the EGF receptor complex, Gab1 is phosphorylated by the EGFR tyrosine kinase domain

PI 3 Kinase and PLGg are recruited and activated by the pTyr motifs of Gab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Gab proteins mediate PI3K and PLCgamma activation

A

3 isoforms, Gab1 ,2 and 3
Have an N terminal PH domain and P-X-X-P motifs (SH3 binding)
Recruited to membranes via their PH domain and via interaction with Grb2

Following recruitment to the EGF receptor complex, Gab1 is phosphorylated by the EGFR tyrosine kinase domain

PI 3 Kinase and PLCgamma are recruited and activated by the pTyr motifs of Gab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Turning off the EGF receptor signalling:

A

EGF receptor activation is transient – for example MAPK activation peaks 5 min after EGF stimulation of cells

Given that activating mutations of the EGFR are oncogenic, turning off EGF signaling is important

Deactivation of EGF signaling is critical and actively regulated:

  • Receptor internalization
  • Negative feedback mechanisms
17
Q

RTK Regulation:

A

Ligand Binding > Receptor Clustering > Clathrin Coated Pit > Early Endosome > Lysosome Receptor Degraded OR Recycling Endosome (And back to ligand binding)

18
Q

Negative feedback of MAPK activation:

A

Ras-GAPs promote the hydrolysis of GTP by RAS thereby blocking its ability to activate Raf

ERK1/2 directing phosphorylate SOS and Raf-1 inhibiting their ability to activate MAPK signaling

ERK1/2 activate a downstream kinase, p90Rsk, which also phosphorylates SOS and turns off MAPK signaling

19
Q

RTKs and disease:

A

Activating mutations in RTKs or their downstream signaling pathways can be oncogenic

  • C-Kit
    Activating mutations in gastrointestinal-stromal tumors, acute myeloid leukemia, mast cell leukemia, and melanoma
  • EGFR/ErbB2
    Activating mutation or gene amplification found in glioblastoma, breast cancer and non small cell lung cancer
  • FGF receptor
    Chromosomal translocations that give active RTK fusion proteins give lymphoblastic lymphoma, multiple myeloma, peripheral T cell lymphoma, and chronic myelogenous leukemia. Activating point mutations found in bladder cancer and cervical carcinoma
    Activating mutations may also promote severe skeletal dysplasias
20
Q

RTK blocking drugs

A

Tyrosine kinase inhibitors can be very effective at blocking oncogenic signaling activity in vivo
They do not (as yet) provide a long term cancer cure